Fact CheckerSign in

NCT06263673CompletedPhase 4

Anti-Diabetic Medications to Fight PD and LBD

Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia

Source: ClinicalTrials.gov · Last updated 28 Jan 2026

Brief summary (registry, in English)

The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.

Status (registry)
Completed
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
18 (actual)
First submitted
9 Feb 2024
Start date
7 May 2024
Primary completion date
8 Jan 2025
Lead sponsor
Mayo Clinic
NCT number
NCT06263673

What you commit to

  • Study type: Interventional · Phase 4
  • Participants enrolled: 18
  • From 7 May 2024 to the primary completion date, 8 Jan 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of high dose steroids.
  • Current systemic chemotherapy.

Other illness

  • Use of insulin or other anti-diabetes medications other than metformin.
  • Bleeding disorder, use of anticoagulants, thrombocytopenia, or severe anemia.
  • Recent (within 30 days) or recurrent (defined as more than one in the past 12 months) urinary tract infection or yeast infection.

Lab values

  • Contraindication to taking a DPP4 inhibitor or SGLT2 inhibitor including: allergy, history of angioedema, pancreatitis, active gallbladder disease, renal impairment with EGFR \< 45).

Other

  • Pregnancy or breastfeeding.
  • Other contraindication that would make study participation unsafe or make study related data unable to be interpreted.

Who the study is looking for

  • Parkinson's disease or Lewy Body Dementia (diagnosis confirmed by neurologist at Mayo Clinic) with stable neurological treatment in the past approximately three months.
  • Glucose intolerance or mild diabetes: The American Diabetes Association criteria for pre-diabetes/ glucose intolerance includes fasting glucose 100-125, random glucose 140-199, or hemoglobin A1C 5.7-6.4% and diabetes is \> 125 mg/dL, \> 200 mg/dL, and 6.5% or greater, respectively (40). It has been previously reported that 50-80% of individuals with Parkinson's disease have abnormal glucose tolerance (17), so this should not limit recruitment.

Age in the registry: 45 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Mayo Clinic Florida
Coordinator of this site? Confirm its status
JacksonvilleUnited StatesUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.